Education
About Us
Working with TipRanks
Follow Us
Inmune Bio Inc (INMB)
NASDAQ:INMB
INMB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $13.30
Previous CloseN/A
Volume114.20K
Average Volume (3M)442.60K
Market Cap
$178.04M
Enterprise Value$78.16M
Total Cash (Recent Filing)$35.85M
Total Debt (Recent Filing)$10.44M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Apr 30, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding22,172,451
10 Day Avg. Volume278,817
30 Day Avg. Volume442,597
Standard Deviation0.31
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4239.16
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit504.27
Enterprise Value/Ebitda-2.56
Forecast
1Y Price Target
$23.40Price Target Upside191.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Inmune Bio News
PremiumCompany Announcements
Inmune Bio Secures License Agreement for CORDStrom Data
PremiumCompany Announcements
Inmune Bio Completes Phase 2 Trial for CORDStrom
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityRecessive dystrophic epidermolysis bullosa (RDEB) could represent a $1B opportunity with potential for premium pricing.
Regulatory ApprovalThe FDA has indicated during a Type C meeting that the data from the study could support a filing.
Bears Say
Financial StabilityINmune announced a $13M equity financing, which should extend the runway through the P2 data.
---
Ownership Overview
20.40% Insiders
4.74% Mutual Funds
7.55% Other Institutional Investors
61.63% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INMB FAQ
What was Inmune Bio Inc’s price range in the past 12 months?
Inmune Bio Inc lowest stock price was $4.32 and its highest was $13.30 in the past 12 months.
What is Inmune Bio Inc’s market cap?
Inmune Bio Inc’s market cap is $178.04M.
When is Inmune Bio Inc’s upcoming earnings report date?
Inmune Bio Inc’s upcoming earnings report date is Apr 30, 2025 which is in 57 days.
How were Inmune Bio Inc’s earnings last quarter?
Currently, no data Available
Is Inmune Bio Inc overvalued?
According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued.
Does Inmune Bio Inc pay dividends?
Inmune Bio Inc does not currently pay dividends.
What is Inmune Bio Inc’s EPS estimate?
Inmune Bio Inc’s EPS estimate is -0.55.
How many shares outstanding does Inmune Bio Inc have?
Inmune Bio Inc has 22,172,451 shares outstanding.
What happened to Inmune Bio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inmune Bio Inc?
Currently, no hedge funds are holding shares in INMB
---
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.40 (191.41% Upside)
$23.40 (191.41% Upside)
Blogger Sentiment
Neutral
INMB Sentiment 50%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.06%
12-Months-Change
Fundamentals
Return on Equity
-98.97%
Trailing 12-Months
Asset Growth
-15.82%
Trailing 12-Months
Company Description
Inmune Bio Inc
Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.
---
INMB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with significant achievements in clinical trial progress and financial stability outweighing the increased net loss and R&D expenses. The company's strategic focus on advancing its Alzheimer's and cancer programs shows promise for future developments.Read More>---
INMB Stock 12 Month Forecast
Average Price Target
$23.40
▲(191.41% Upside)
Technical Analysis
Cassava Sciences
―
Axon Enterprise
―
Aurinia Pharmaceuticals
―
Anavex Life Sciences
―
Annovis Bio
―
Best Analysts Covering INMB
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
-3.63%
reiterated a buy rating 21 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -3.63% per trade.
---